Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidinoethyldisulfide SCHEMBL145590 | 0.85 | TSHR (0.69) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| Guanidinoethyldisulfide SCHEMBL1321518 | 0.83 | TSHR (0.67) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL13035000 | 0.79 | TSHR (0.58) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL27499299 | 0.77 | TSHR (0.60) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL12040362 | 0.77 | TSHR (0.60) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL19224312 | 0.74 | TSHR (0.30) | TSHRHIF1A | |
| SCHEMBL14619329 | 0.73 | CYP1A2 (0.46) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL10311296 | 0.72 | TSHR (0.53) | TSHRHIF1AMEN1CYP1A2KMT2A | |
| SCHEMBL7063396 | 0.72 | — | — | |
| SCHEMBL7125618 | 0.71 | TSHR (0.53) | TSHRHIF1AMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | TSHR 3130/4885HIF1A 3011/4885MEN1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.